The 4th Annual Focused Ultrasound Symposium in October highlighted many promising new applications of the technology, including the use of this noninvasive therapeutic technology to treat conditions as diverse as Parkinson’s disease and essential tremor, obsessive compulsive disorder, several cancers, hypertension, and uterine fibroids.
The preliminary data and newly initiated studies suggest focused ultrasound is “on the precipice, shifting from an innovative early-stage therapy into a tool poised to disrupt the provision of care for some of medicine’s most vexing conditions,” said Andrew von Eschenbach, MD, former FDA commissioner, former director of the National Cancer Institute, and member of the Focused Ultrasound Foundation board of directors.
“We host this Symposium to serve as a crucible for fostering collaboration across the field,” said Neal Kassell, MD, founder and chairman of the Focused Ultrasound Foundation. “And having more than 400 experts travel from 24 countries to share their research demonstrates the impressive potential of this noninvasive technology to transform the treatment of many serious medical conditions.”
